Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ... https://t.co/nHiLA33jHl
RT @Oncotarget: In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of comp…
In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of computer modeling or computer simulation. Read more in a paper: https://t.co/WlxfSfsLHq #Facts #didyouknow #machinelearning #AI #medEd #
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach https://t.co/nHiLA33jHl
RT @Oncotarget: In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of comp…
RT @Oncotarget: In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of comp…
RT @Oncotarget: In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of comp…
RT @Oncotarget: In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of comp…
In silico: A pseudo-Latin term, used in scientific experiments and research, meaning to conduct or produce by means of computer modeling or computer simulation. Read more in the study: https://t.co/WlxfSfsLHq #FactFriday #machinelearning #AI #medEd #simul
Watch a short video about the Oncotarget paper trending this week. Read the full study here: https://t.co/WlxfSfbaiQ #OncotargetShort #TrendingWithImpact #lungcancer #science #medicine #MachineLearning https://t.co/dUdp3y50qD
RT @anaxomics: We are proud to share with you the publication of a Head to Head in silico study between ALK inhibitors for the treatment fo…
We are proud to share with you the publication of a Head to Head in silico study between ALK inhibitors for the treatment for ALK+ NSCLC developed with @GTRecerca @ICOnoticies @Takeda_ES @mire_coma @baldo63 @XouseMas https://t.co/672kGz8XK5 #ArtificialInt
Research paper: "Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach:" https://t.co/K1KRPhBkdN #NSCLC #lungcancer #cancerresearch